Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
Curr Oncol Rep. 2012 Oct;14(5):424-32. doi: 10.1007/s11912-012-0258-4.
The transformation of follicular lymphoma to an aggressive lymphoma is a well-recognised complication that occurs at a rate of approximately 3 % a year for the first 10 years of observation. Transformation is accompanied by increased risk of refractoriness and a poor expectation of survival. Genetic and epigenetic triggers for transformation have been described. Prior to routine use of rituximab, transformed lymphoma was managed in a fashion similar to that for de novo diffuse large B-cell lymphoma, with generally poor results. Rituximab appears to have improved outcomes. Some centres, including our own, use high-dose chemotherapy with stem cell transplantation as consolidation for those with responsive disease. Here, we focus on transformed follicular lymphoma, and provide an overview of the current literature and our approach to management.
滤泡性淋巴瘤向侵袭性淋巴瘤的转化是一种公认的并发症，在观察的前 10 年中，其发生率约为每年 3%。转化伴随着耐药风险的增加和生存预期的恶化。已经描述了转化的遗传和表观遗传触发因素。在常规使用利妥昔单抗之前，转化性淋巴瘤的治疗方式与新发弥漫性大 B 细胞淋巴瘤相似，结果通常较差。利妥昔单抗似乎改善了结果。一些中心，包括我们自己的中心，将高剂量化疗联合干细胞移植作为缓解疾病的巩固治疗。在这里，我们专注于转化滤泡性淋巴瘤，并提供当前文献综述和我们的治疗方法概述。
